Keyphrases
Lipopolysaccharide
100%
Neuroinflammation
100%
Lipopolysaccharide-induced
100%
Behavioral Impairment
100%
Frontal Cortex
60%
Brainstem
60%
Cerebellum
60%
Sickness
60%
Inflammation
40%
Interleukin-1β
40%
CXCL10
40%
Interleukin-6
40%
Anxiety-like Behavior
40%
Chemokine (C-C motif) Ligand 2 (CCL2)
40%
Neurological Disorders
40%
Differential Effects
40%
Sex-specific
20%
Brain Regions
20%
Hippocampus
20%
Chemokines
20%
Sex Differences
20%
Anti-inflammatory Activity
20%
Astroglial Cells
20%
Inflammatory Pathways
20%
Whole Brain
20%
Open Field Test
20%
Monocyte Chemoattractant protein-1 (MCP-1)
20%
β-funaltrexamine
20%
C57BL
20%
Enzyme-linked Immunosorbent Assay (ELISA)
20%
Mu-opioid Receptor Antagonist
20%
Tumor Necrosis Factor-α
20%
Inflammatory Chemokines
20%
Elevated Plus Maze Test
20%
Dosing Schedule
20%
Two-way Analysis of Variance
20%
Potential Treatments
20%
Interferon-induced Protein
20%
Treatment Timing
20%
Regional Effects
20%
Brain Hippocampus
20%
Neuroprotective Action
20%
Pharmacology, Toxicology and Pharmaceutical Science
Lipopolysaccharide
100%
Lipopolysaccharide-Induced Neuroinflammation
100%
Disease
50%
Tumor Necrosis Factor
50%
Interleukin 6
50%
Cytokine
33%
Inflammation
33%
Chemokine
33%
Neurologic Disease
33%
Anti-Inflammatory Drug
16%
Interferon
16%
Mu Opiate Receptor Antagonist
16%
Enzyme-Linked Immunosorbent Assay
16%
Neuroprotective Agent
16%
Interleukin 1
16%
C57BL 6 Mouse
16%
Beta Funaltrexamine
16%
Monocyte Chemotactic Protein 1
16%
Neuroscience
Lipopolysaccharide
100%
Behavior (Neuroscience)
44%
Frontal Lobe
33%
Brainstem
33%
Cerebellum
33%
Interleukin 6
33%
Blood Plasma
33%
Chemokine
22%
CXCL10
22%
Hippocampus
22%
CCL2
22%
Neurological Disorder
22%
In Vitro
11%
Interleukin 1
11%
Interferon
11%
Monocyte Chemotactic Protein 1
11%
Neuroprotective Agent
11%
Anti-Inflammatory
11%
μ-Opioid Receptor
11%
Elevated Plus Maze
11%
Tumor Necrosis Factor Alpha
11%
Narcotic Antagonist
11%